

10 November 2016

Placement to Chinese Pharmaceutical and Investment Group

Highlights

- Investment by Chinese pharmaceutical and traditional medicine group – Tianjin Tongrentang
- \$0.6m placement at 1 cent per share to new strategic investor
- Entitlement issue offer at the same price for existing shareholders
- Proceeds to increase EVE's investment in Omni Innovation to ~ 40%

Placement

EVE will conduct a placement at 1 cent per share to raise \$600,000 before costs by issuing 60,000,000 new shares to a new strategic investor, the Tianjin Tongrentang Group via its Australian subsidiary TRT Investment Group. The placement, conducted at the last closing price, will fall within the Company's 15% placement capacity available under ASX Listing Rule 7.1. New shares issued in the placement are expected to be allotted this week.

Tianjin Tongrentang Group

Tianjin Tongrentang Group is one of China's oldest pharmaceutical and traditional chinese medicine (TCM) enterprises. It specialises in research and development, production and sales of TCM and owns two pharmaceutical production and sale enterprises - Tianjin Tongrentang and Hongrentang which are recognised as two of the forty-three time-honoured pharmaceutical brands granted by the Ministry of Commerce.

Tianjin Tongrentang and Hongrentang hold a combined number of 99 valid drug approvals, including a national-protected variety, 20 exclusive varieties and 29 drugs that are included in China's national medical insurance.

Tianjin Tongrentang has a well-developed, extensive distribution network throughout China.

Entitlement Issue

In addition to the placement, EVE will also be offering existing shareholders the opportunity to participate in a non-renounceable entitlement issue at the same price as the placement on a 1:6 basis raising up to \$1,959,167. The entitlement issue will be managed by Westar Capital Ltd.

Further details about the entitlement issue will be released in due course.

Funds from both the placement and entitlement issue will be applied to the second tranche investment in Omni Innovation, taking the Company's interest to approximately 40%. Additional funds will be used to review new investments and for working capital.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

About Omniblend Innovation

Omniblend Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

In August 2016 the Company launched its maiden product, Faulding® GlucoControl™ for use in the dietary management of type 2 diabetes and pre-diabetes.

For more information, please visit www.obinnovation.com.au

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au